Method validation was performed by applying the developed MS quantitative processing method to the triplicate injections of a HEK293 cell derived AAV2 sample, whose VP separation was performed in the same sequence as the baculovirus/Sf9 derived AAVs. All 3 full-length AAV2 VPs were correctly identified without false positive identifications from other serotypes. To illustrate its adaptability, this method was then applied to select HEK293 derived AAV2 samples analysed in Section 3.3. Here the samples analysed at 45°C column temp and 15K MS resolution as well as the samples analysed at 25°C and 45K MS resolution were selected. By simply adjusting the expected retention time to correspond with the new retention times obtained under the new experimental conditions, correct identification of the AAV2 VPs was obtained, demonstrating that this method can be quickly and easily modified to accommodate changes in the LC-MS method parameters. The process described above was then also applied to create a PTM monitoring method allowing further investigation into VP PTMs of a specific serotype (See Table for parameters). Using the HEK293 derived AAV2 samples analysed at 25°C and with an MS resolving power of 45K as a proof of concept, we developed and optimized a method for the identification and characterization of fulllength VP proteoforms. When put to the test, all VP proteoforms discussed in Section 3.3 were successfully detected. The ability to characterize the VP variants and proteoforms under each VP peak has the potential to ensure product quality and consistency, when used for lot or batch comparisons.